Lisata Therapeutics to Attend May 2024 Industry and Investor Events

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company based in Basking Ridge, N.J., is advancing the development of innovative therapies for advanced solid tumors and other serious diseases. The company recently announced its participation in several key industry events scheduled for May 2024.

The first event Lisata will attend is the Pharma Partnering U.S. Summit, held in San Diego, California, on May 14-15, 2024. Representing the company will be Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel. Mr. Imam will be available for one-on-one meetings with registered attendees during the summit.

Next, Lisata will participate in the BioNJ BioPartnering Conference, which is taking place virtually from May 15-17, 2024. Tariq Imam will again represent the company and will be available for individual meetings with participants.

Following these events, Lisata will attend the Pharma Partnering EU Summit in Basel, Switzerland, on May 22-23, 2024. David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, is scheduled to present on Wednesday, May 22, 2024, at 12:30 p.m. CEST. Dr. Mazzo will also be available for one-on-one meetings with registered attendees throughout the summit.

On May 31, 2024, Lisata will participate in the 10th Annual Oncology Innovation Forum in Chicago, Illinois. Dr. Mazzo is set to present at 10:50 a.m. Central Time / 11:50 a.m. Eastern Time. The management team will be available for individual meetings with registered attendees during the event.

Additionally, Lisata will be present at the 2024 ASCO Annual Meeting, held from May 31 to June 4, 2024, in Chicago, Illinois. Although the company will not have a poster presentation at this year’s meeting, Lisata's management team will be in the Chicago area and available for one-on-one meetings throughout the duration of the ASCO meeting dates.

Lisata Therapeutics is dedicated to the discovery, development, and commercialization of innovative therapies aimed at the treatment of advanced solid tumors and other significant diseases. The company’s leading product candidate, certepetide, is an investigational drug designed to enhance the effectiveness of co-administered or tethered anti-cancer drugs by activating a novel uptake pathway, enabling better targeting and penetration of solid tumors. This product is based on Lisata’s proprietary CendR Platform® Technology. Lisata has already established notable commercial and research partnerships and anticipates announcing numerous clinical and business milestones over the next two years. The company projects that its current development and business plans are sufficiently funded through these milestones and into early 2026.